Espero BioPharma CEO and BioFlorida Member Quang Pham selected as EY Entrepreneur Of The Year® 2017 Award finalist in Florida

JACKSONVILLE, Fla, May 4, 2017 – EY today announced that Quang Pham, Chief Executive Officer of Espero BioPharma, Inc., is a finalist for the Entrepreneur Of The Year® 2017 Award in Florida. The awards program, which is celebrating its 31st year, recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal […]

Read more

Espero Pharmaceuticals and Armetheon to Merge and Create a 
Premier Cardiovascular Focused Biopharmaceutical Company

JACKSONVILLE, Fla. and MENLO PARK, Calif. (March 30, 2017) – Espero Pharmaceuticals, Inc., a privately held, commercial-stage cardiovascular pharmaceutical company, and Armetheon, Inc., a privately held, late-clinical stage pharmaceutical company developing innovative novel drugs addressing major unmet needs in cardiovascular diseases, today announced their plans to merge. Upon completion of the merger, which is expected […]

Read more

Espero Acquires DURLAZA® (aspirin) Extended Release Capsules 
for Secondary Prevention of Stroke and Acute Cardiac Events

JACKSONVILLE, Fla. (February 7, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, today announced that the company has acquired the global rights to DURLAZA® (aspirin) Extended Release Capsules.Company officials will provide an update on February 13, 2017 at the BIO CEO & Investor Conference held at the Waldorf Astoria New York. DURLAZA is […]

Read more

GONITRO™ to Participate in First-of-its-Kind 
Comparative Effectiveness ISCHEMIA Clinical Trial Sponsored by the National Institutes of Health

JACKSONVILLE, Fla. (Jan. 19, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, will donate GONITRO™ (nitroglycerin sublingual powder) to the ongoing International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) clinical trial and to the ISCHEMIA-Chronic Kidney Disease (CKD) ancillary trial. The company’s executives provided an update during last week’s […]

Read more

Espero Pharmaceuticals to Present at 9th Annual Biotech Showcase

JACKSONVILLE, Fla. (December 20, 2016) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, announced today that the company has been invited to present at the 9th Annual Biotech Showcase in San Francisco from January 9-11, 2017. Quang Pham, Chief Executive Officer, and Jeff Cole, President and Chief Financial Officer, will provide an update on […]

Read more

Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO™ (Nitroglycerin) Sublingual Powder in the U.S.

New Short-Acting Nitrate Powder Now Available in Single Dose Packets 
for Acute Relief of an Angina Pectoris Attack JACKSONVILLE, Fla. (Sept. 27, 2016) – Espero Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced the commercial availability of GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due […]

Read more

Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO™ (Nitroglycerin) Sublingual Powder

Available in Single Dose Packets, GONITRO™ is Approved For 
Acute Relief of an Angina Pectoris Attack Due to Coronary Artery Disease JACKSONVILLE, Fla. (August 30, 2016) – Espero Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that DDB Health, an Omnicom Health Group company, as its agency of record for GONITRO™. Omnicom is […]

Read more

Espero Pharmaceuticals Receives FDA Approval for GONITRO™ (Nitroglycerin) Sublingual Powder

JACKSONVILLE, Fla. (June 14, 2016) – Espero Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. With this approval, GONITRO™ is the first and […]

Read more

Espero Pharmaceuticals Announces Board and Executive Appointments

• Former CEO of Novartis and Astra-Merck Wayne Yetter joins Board • Co-founder Jeff Cole appointed President, CFO and Director • Sean Purdy hired as VP of Commercial Operations JACKSONVILLE, FL, February 17, 2016 – Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced the appointment of industry veteran Wayne Yetter as […]

Read more

Espero Pharmaceuticals to Present at Biotech Showcase 2016

JACKSONVILLE, Fla.–(BUSINESS WIRE)–Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced its participation in the 8th Annual Biotech ShowcaseTM Conference in San Francisco, CA on January 11-13, 2016. Mr. Quang Pham, Founder and CEO, will discuss recent Company developments in his presentation on Tuesday, January 12 at 2:45pm PST at the Parc […]

Read more

1 2